ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KURA vs UNH // REVENUE GROWTH (YOY)

Kura Oncology Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: KURA 1 — UNH 9
▲ REVENUE GROWTH (YOY) LEADER: KURA
revenue-growth
25.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KURA VS. UNH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KURA UNH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 88.57% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 11.47% -46.47 UNH /roic <GO>
EV/EBITDA & P/E Valuation — 16.4x — TIE /valuation <GO>
Free Cash Flow Yield -7.53% 6.48% -14.01 UNH /fcf-yield <GO>
Operating Margin -60.00% 4.82% -64.82 UNH /operating-margins <GO>
Net Profit Margin -60.00% 3.14% -63.14 UNH /net-margins <GO>
Revenue Growth (YoY) ACTIVE 25.20% 6.46% +18.74 KURA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.28% -2.28 UNH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 3.12 -2.92 UNH /balance-sheet <GO>
Piotroski F-Score Quality 4/9 7/9 -3.00 UNH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — 6.74% — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.1 59.2 -6.10 UNH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.33 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 17.7x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $939.4M $368.83B -$367.89B UNH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KURA REV UNH REV KURA GROSS % UNH GROSS % KURA FCF UNH FCF
FY 2025 $67.5M $447.57B — 88.7% -$70.7M $16.07B
FY 2024 $53.9M $400.28B — 88.3% $133.8M $20.70B
FY 2023 $0 $371.62B — 89.6% -$124.8M $25.68B
FY 2022 — $324.16B — 89.6% — $23.40B
FY 2021 — $287.60B — 89.2% — $19.89B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KURA // BETA —
UNH // BETA 0.33